- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | PharmAla Biotech: PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License | 1 | GlobeNewswire (USA) | ||
| 07.11. | PharmAla Biotech: PharmAla to supply LaNeo MDMA for Clinical Trial at Yale | 2 | GlobeNewswire (USA) | ||
| 21.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to Mt. Sinai hospital | 4 | Stockwatch | ||
| 21.10. | PharmAla Biotech: PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 08.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to University of Texas | 2 | Stockwatch | ||
| 08.10. | PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial | 4 | Benzinga.com | ||
| 08.10. | PharmAla Biotech: PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 02.10. | Pharmala Biotech Holdings Inc: Pharmala Biotech to supply MDMA to Harvard's Maclean | 1 | Stockwatch | ||
| 02.10. | PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial | 2 | Benzinga.com | ||
| 02.10. | PharmAla to supply Harvard Medical School trial with MDMA | 4 | The Market Herald Canada | ||
| 02.10. | PharmAla Biotech: PharmAla to supply Harvard Medical School's Maclean Hospital with LaNeo MDMA | 1 | GlobeNewswire (USA) | ||
| 11.09. | Pharmala Biotech Holdings Inc: Pharmala to supply MDMA for Johns Hopkins trial | 1 | Stockwatch | ||
| 11.09. | PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract | 2 | Benzinga.com | ||
| 11.09. | PharmAla Biotech: PharmAla to supply Johns Hopkins Medicine for Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 22.08. | Pharmala Biotech Holdings Inc: Pharmala appoints Avery as CFO | 1 | Stockwatch | ||
| 22.08. | PharmAla Biotech appoints William Avery as finance chief | 1 | Seeking Alpha | ||
| 22.08. | PharmAla Biotech: PharmAla Launches MDMA Clinical Trial Tool for Researchers | 1 | GlobeNewswire (USA) | ||
| 10.08. | Pharmala Biotech Holdings Inc: Pharmala disappointed by FDA decision for MDMA therapy | 1 | Stockwatch | ||
| 10.08. | PharmAla Biotech: PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002 | 310 | GlobeNewswire (Europe) | TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing... ► Artikel lesen | |
| 30.07. | Pharmala Biotech Holdings Inc: Pharmala receives U.S. patent, approves CEO contract | 1 | Stockwatch |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,835 | -0,71 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
| QIAGEN | 40,140 | +3,35 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
PHARMALA BIOTECH HOLDINGS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.
